Citius Pharmaceuticals Inc. Common (CTXR) Stock Price

CTXRStock
$0.6057.38%52W
Market Cap$16.57M
P/E
PEG Ratio
Div yield
Beta0.98

CTXR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.00%
Price vs S&P 500 (4W)12.49%
VGM Score31.72

CTXR Earnings Surprise History

Q2 25-0.80est. -0.21
Q3 25-0.11est. -0.24
Q4 25-0.38est. -0.30
Q1 26-0.95est.
Q2 26-0.34est. -0.36

CTXR Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.00
4.00
4.00

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
CTXRCitius Pharmaceuticals Inc. Common
D$0.60
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Citius Pharmaceuticals Inc. Common

Citius Pharmaceuticals develops first-in-class targeted oncology therapies, with LYMPHIR—an engineered IL-2 diphtheria toxin fusion protein—as its flagship product candidate. The company addresses unmet medical needs in oncology and adjunct cancer care with a lower development risk profile than typical new chemical entities.